Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
HONG KONG, July 13, 2021--In early May, Xenios AG, a Fresenius Medical Care company, received approval for two patient kits in China. It follows NMPA’s approval of the Xenios console back in December 2020. As a result, a complete Xenios system is now permitted for ECMO therapy in China.
Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.